ESMO Gynaecological Cancers Congress 2022
![ESMO Gynae 2022_delegates 2](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2022/esmo-gynae-2022_delegates-2/11392164-1-eng-GB/esmo-gynae-2022_delegates-2_i770.png)
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
![ESMO Gynae 2022_audience](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2022/esmo-gynae-2022_audience/11390484-1-eng-GB/esmo-gynae-2022_audience_i770.png)
What is the state of play for molecular profiling in gynaecological malignancies?
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
![ESMO Gynae 2022_poster area](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2022/esmo-gynae-2022_poster-area/11390229-1-eng-GB/esmo-gynae-2022_poster-area_i770.png)
How to improve cervical cancer screening in low- or middle-income countries?
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
![Eric Pujade-Lauraine](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/eric-pujade-lauraine/11281290-2-eng-GB/eric-pujade-lauraine_i770.jpg)
Recent advances fuelled by translational research reflect a greater focus on patients’ quality of life
The advent of PARP inhibitors, an increased use of laparoscopy for patient selection and a more prominent role of PROs have been facilitated by international collaborations
![DR @ Congress](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/dr-congress/9268143-1-eng-GB/dr-congress_i770.jpg)
Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
![ESMO Gynae 2022_venue](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2022/esmo-gynae-2022_venue/11390214-1-eng-GB/esmo-gynae-2022_venue_i770.png)
Managing ovarian cancer in the PARP inhibitor era
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022